Canary RX Inc. (CNW Group/Target Group Inc.)

Canary RX Inc., Awarded 3 Licenses from Health Canada to Cultivate, Process and Sell Cannabis Pursuant to the Cannabis Act

 Target Group Inc has been granted licenses to cultivate, process and sell cannabis pursuant to the Cannabis Act (Bill C-45). Strategically located just outside of Toronto, ON, Canary RX will begin cultivating cannabis in its 44,000 square foot facility, producing 3600 kilograms annually.

These Standard Licenses enable Canary to produce approximately 3,600kg of dried cannabis flower per year. Canary has curated a bank of 3,500 seeds, comprised of more than 125 strains, including the entire Serious Seeds collection. The Company has the capacity to grow 8 different strains at a time, within the facility’s 8 separate flower rooms. 

“Canary first applied for a cultivation license under the MMPR (Marihuana for Medical Purposes Regulations) in 2015. Since then, dozens of people in Canary, Target., and our networks worked together to reach this milestone. We’re proud of our people, we’re proud of our facility, and now, we will focus on our business goals to expand Canary products and presence in our selected markets.”, said Randy MacLeod, President & CEO of Canary.  

“We could not be more excited to have received licenses to cultivate, process and sell cannabis under The Cannabis Act. Our committed team understands that these licenses are just the beginning of what’s to come for Target and Canary. Target, through its subsidiaries, aims to be a leading provider of cannabis products, services, and supporting technologies to both the adult-use and medical markets. We’d like to thank all of our shareholders that have contributed to this achievement over the past few years and we look forward to continuing to grow and promote the Canary RX brand”, said Rubin Schindermann, CEO of Target Group Inc.